A personalized targeted treatment approach to guide SCLC management has yet to materialize despite the high rate of genomic perturbations, in part because the most common alterations occur in tumor suppressor genes (TP53 and RB1) that are not yet targetable by pharmacological approaches [18,19,20,21]. Here, TP53 is linked to small cell lung carcinoma.